Nile Pharmaceuticals results, Fiscal year 2022
Net profit, assets, equity and cash flow for Fiscal year 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit89.67 millionEGP · +39.2% vs the same period a year earlier
Total assets769 millionEGP · +6.8% vs the same period a year earlier
Shareholders' equity431 millionEGP · +16.0% vs the same period a year earlier
Operating cash flow4.91 millionEGP · −93.8% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Fiscal year 2022 was about 89.67 million EGP, up +39.2% from 64.42 million EGP in Fiscal year 2021.
- Total assets at the end of Fiscal year 2022 were about 769 million EGP, and shareholders' equity about 431 million EGP.
- Operating cash flow for Fiscal year 2022 was positive at 4.91 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2021Change
Net profit89.67 million64.42 million+39.2%
Gross profit535 million502 million+6.8%
Total assets769 million720 million+6.8%
Total liabilities339 million349 million−3.0%
Shareholders' equity431 million371 million+16.0%
Total liabilities and equity769 million720 million+6.8%
Operating cash flow4.91 million79.47 million−93.8%
Investing cash flow-48 million-4.29 million−1019.7%
Financing cash flow-12.62 million-45.2 million+72.1%
Net change in cash-55.71 million29.99 million−285.8%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy